投稿信息
投稿信息
投稿命中率
審稿費用
暫無數(shù)據(jù)
版面費用
暫無數(shù)據(jù)
中國人發(fā)表比例
2023年中國人文章占該期刊總數(shù)量46.02% (2022年為12.31%)
自引率
4.8 %
年文章數(shù)
4419
作者需知
暫無數(shù)據(jù)
NCBI查詢
偏重的研究方向
期刊簡介
稿件收錄要求
稿件收錄要求
Clinica Chimica Acta publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids, cells or tissues The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are considered in they are clearly and directly relevant to human disease. Development and evaluation of novel analytical methologies where applicable to clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. In addition to original Research Communications the journal publishes: (1) Short Communications-concise reports of limited scope which offer conclusive results or document methodological advances; (2) Letters to the Editor, commenting on papers published in Clinica Chimica Acta - these should be less than 400 words and may include 1 illustration or 1 table; (3) Invited Critical Reviews of recent central developments in medical biochemistry and laboratory medicine; (4) case reports involving interesting or novel clinical laboratory data; (5) Newsletters of Scientific Societies; (6) Meeting announcements. Typescripts submitted to Clinica Chimica Acta should not have been published previously and should not be under consideration for publication elsewhere. The agreement of all named authors to the submission must be affirmed. Relevant ethical approval must be noted for investigations involving human or animal subjects. Authors are invited to consult any member of the Editorial Board, if in doubt about any aspect of scope, format or content of a proposed paper.
常用鏈接
期刊論壇
|
中國SCI論文
|
期刊介紹
|
投稿信息
|
雜志官網(wǎng)
|
投稿鏈接
|
作者需知
|
PMC鏈接
|
Pubmed全文檢索
